Biotech's "great run" will continue despite a bumpy April, which came on the heels of a big jump in the sector, one analyst said.» Read More
Celgene's phase 2 study of its experimental Crohn's disease pill was published in The New England Journal of Medicine. Phase 3 is expected to start this year, reports CNBC's Meg Tirrell.
As Biogen Idec gets set to reveal new data on its Alzheimer's drug, BIIB037, investors should be prepared for a big move either way.
Studies of a new class of cholesterol-lowering drugs signal that they can reduce by half the risk of heart attack.
Here are the stocks to watch heading out of this weekend's American College of Cardiology conference in San Diego.
Biotechs are on a tear. Akiva Felt, Oppenheimer, provides perspective on the biotech boom, and his favorite picks in the space.
A destructive insect's growing resistance to genetically modified corn seeds is costing American farmers as much as $2 billion annually.
Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.
Acadia Pharmaceuticals fell more than 22 percent in after-hours trading Wednesday on news that its CEO is retiring.
Dr. Kathryn Schmitz, Professor of Epidemiology at University of Pennsylvania, speaks about a new app, "Share the Journey", which is said to track issues related to breast cancer treatment.
Our goal is to offer the most choice at the lowest price, says Dr. Steve Miller, Express Scripts CMO, discussing what's behind the rising costs of specialty medications and how drugmakers plan to keep costs down.
CNBC's Meg Tirrell has the details on a report from Express Scripts which shows prices on some prescription drugs are soaring.
Spending on prescription drugs in the U.S. rose 13.1% in 2014, the biggest increase in more than a decade, according a report from Express Scripts.
The old-line tech firms, along with Apple, are minting bigger dividends for investors.
The Food and Drug Administration has approved the first so-called biosimilar drug for use in the United States. The New York Times reports.
Jason Kolbert, Maxim Group, provides perspective on big M&A deals in the biotech space.
Bristol-Myers hit a 14-year high after the company won expanded approval for its lung cancer drug more than 3-months ahead of schedule. Details, with CNBC's Meg Tirrell.
CNBC's Meg Tirrell has details on the biotech deal between AbbVie and Pharmacyclics.
Johnson & Johnson is nearing a deal to acquire U.S. cancer drugmaker Pharmacyclics.
The drugmaker's new policies prohibit the direct-to-prison sales of two of its drugs used in executions.
Constant vigilance is the method the Florida Keys has used to ward off mosquito-borne illnesses, but new methods may be on the horizon.
Get the best of CNBC in your inbox